A Aralex Aachen research explorer

June 17, 2024 article Open access

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition

American Journal of Hematology

DOI: 10.1002/ajh.27412 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 4 stored of 48

Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada
2026 Hematology article Immunology and Microbiology Complement system in diseases Open access

1

citations
Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies
2025 Annals of Hematology article Immunology and Microbiology Complement system in diseases Open access

1

citations
Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria
2025 British Journal of Clinical Pharmacology article Immunology and Microbiology Complement system in diseases Open access

10

citations
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria
2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access

52

citations

4 results

References 3

3 results